Ikena Oncology Inc. has announced a 1-for-12 reverse stock split of its common stock, effective around the end of July 2025. This move will reduce the number of issued and outstanding shares from approximately 48.2 million to approximately 4 million. The company's common stock will begin trading on Nasdaq on a split-adjusted basis at that time, coinciding with the anticipated closing of its merger with Inmagene Biopharmaceuticals. Following the merger, the combined company will be renamed ImageneBio, Inc. and trade under the ticker symbol "IMA."
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikena Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495023-en) on July 15, 2025, and is solely responsible for the information contained therein.